Genmab A/S
GMABHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeGenmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company carries a $14.64B market cap, placing it firmly in the large-cap category. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Market Cap
$14.64B
Beta
0.69
P/E (TTM)
18.21
P/E (Fwd)
13.03
EPS (TTM)
$1.31
EPS (Fwd)
$1.83
ROE
15.0%
ROA
8.5%
Cash
$1.52B
Total Debt
$5.35B
Free CF
$830.4M
52W Change
9.5%
Annual Financials
Cash vs Debt
Genmab A/S carries $5.35B in total debt against $1.52B in cash reserves — debt is roughly 3.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $830.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 15.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.09B (2022) to $3.72B (2025), reflecting a 78% increase over the period.
The relatively low beta of 0.69 suggests GMAB is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Genmab A/S and its sector.